newsfilter
← Latest News
GlobeNewswire·

VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio

  • VERAXA Biotech AG appointed Christoph Erkel, Ph.D., as Chief Scientific Officer effective immediately.
  • Erkel previously served as Vice President of Research & Development at VERAXA & will direct the BiTAC® platform to accelerate cancer treatment development for solid tumors.
  • Rick Austin, Ph.D., is departing the company following a successful transition period.
  • Erkel brings 20 years of expertise in antibody therapeutics, spanning early-stage discovery to IND submission.
  • Prior to VERAXA, Erkel led immuno-oncology programs at MorphoSys AG (acquired by Novartis) & held senior roles at Sloning BioTechnology GmbH.
  • Erkel holds a Ph.D. in Biology from Philipps University & conducted postdoctoral research at the Max Planck Institute for Terrestrial Microbiology.
  • Chairman Oliver R. Baumann thanked Austin for his contributions while welcoming Erkel to lead the expansion of the BiTAC technology platform.
  • VERAXA is advancing a pipeline of conditionally active T cell engagers, bispecific ADCs, & proprietary BiTAC formats into clinical development.
  • The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL).